Designing nanomedicine for immuno-oncology

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text

Life Sciences, Immunology, Oncology +17

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations

Medicine, Immunology, Oncology +17

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Yasuhiro Matsumura, Hiroshi Maeda · PubMed · 1986 · 6.8K citations

Medicine, Oncology, Pharmacology +12